Dublin, Sept. 09, 2021 (GLOBE NEWSWIRE) -- The "Global Next-Generation Sequencing Data Analysis Market Size, Share & Trends Analysis Report by Product, by Workflow, by Mode, by Read Length, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global next-generation sequencing data analysis market size is expected to reach USD 1.72 billion by 2028 registering a CAGR of 15.02%.
Key drivers contributing to market expansion include the growing adoption of sequencing platforms for clinical diagnosis because of a significant reduction in the cost of installation. The easy availability of genomic and proteomic data is also expected to create lucrative growth opportunities in this market during the forecast period.In addition, a decrease in the cost of sequencing is expected to increase the adoption of next-generation sequencing (NGS), which, in turn, is likely to boost the market growth. Availability of tools, such as Agilent's HaloPlex capture system and Targeted Methyl-Seq platform from EpiGentek Group Inc., has helped in the determination of DNA methylation profiles in individual genomes. An increase in the adoption of bisulfite-methylation for targeted sequencing and targeted methylation NGS data analysis methods is anticipated to propel market growth.EpigenDx, CD Genomics, Novogene Co., Ltd., and Epigentek Group, Inc. are the key players that offer methylation sequencing and targeted bisulfite sequencing data analysis services. The launch of new products will further boost revenue generation in the market. Major market participants have undertaken various strategic initiatives to strengthen their position in the market. For instance, in January 2021, Transnetyx, Inc. collaborated with One Codex to provide end-to-end analysis and microbiome sequencing services. This is expected to offer affordable sequencing analysis services to researchers.Next-Generation Sequencing Data Analysis Market Report Highlights
Key Topics Covered: Chapter 1 NGS Data Analysis Market: Methodology and ScopeChapter 2 NGS Data Analysis Market: Executive SummaryChapter 3 NGS Data Analysis Market: Market Variables, Trends, and Scope3.1 Market Trends and Outlook3.2 Market Segmentation and Scope3.3 Market Dynamics3.3.1 Market driver analysis3.3.1.1 Demand for efficient algorithms and tools for analysis of large amount of data generated by sequencers3.3.1.2 Introduction of technological advancements in cloud computing and data integration3.3.1.3 Increasing penetration of the NGS technology in personalized medicine and precision diagnosis3.3.1.4 Rising academic research based on NGS protocols3.3.2 Market restraint analysis3.3.2.1 Challenges in sequence compression and data storage3.3.2.2 Selection of appropriate algorithms and Parallelizing scientific workflows3.3.2.3 Budget and time constraints3.4 Next generation sequencing data analysis company heat map analysis, 20193.4.1 Company size3.4.2 Geographical presence3.4.3 Product portfolio3.4.4 Strategic initiatives3.5 Business Environment Analysis3.5.1 SWOT analysis; by factor (political & legal, economic and technological)3.5.2 Porter's Five Forces Analysis3.6 Penetration and Growth Prospect Mapping for Workflow, 2020Chapter 4 NGS Data Analysis Market: Product Estimates and Trend Analysis4.1 Market: Product Movement Analysis4.2 NGS Data Analysis Services4.2.1 Market, 2017 - 2028 (USD Million)4.3 NGS Commercial Software4.3.1 Market, 2017 - 2028 (USD Million)4.3.2 Platform OS/UI4.3.2.1 Market, 2017 - 2028 (USD Million)4.3.3 Analytical software4.3.3.1 Market, 2017 - 2028 (USD Million)4.3.3.2 Alignment tools & software4.3.3.2.1 Market, 2017 - 2028 (USD Million)4.3.3.2.2 DNA sequencing Alignment4.3.3.2.2.1 Market, 2017 - 2028 (USD Million)4.3.3.2.3 RNA sequence alignment4.3.3.2.3.1 Market, 2017 - 2028 (USD Million)4.3.3.2.4 Protein sequence alignment4.3.3.2.4.1 Market, 2017 - 2028 (USD Million)4.3.3.3 QC/Pre-processing tools4.3.3.3.1 Market, 2017 - 2028 (USD Million)4.3.3.4 Others4.3.3.4.1 Market, 2017 - 2028 (USD Million)Chapter 5 NGS Data Analysis Market: Workflow Business Analysis5.1 NGS Data Analysis Market: Workflow Movement Analysis5.2 Primary Data NGS Analysis5.2.1 Market, 2017 - 2028 (USD Million)5.3 Secondary Data Analysis5.3.1 Market, 2017 - 2028 (USD Million)5.3.2 Read mapping5.3.2.1 Market, 2017 - 2028 (USD Million)5.3.3 Variant alignment & variant calling5.3.3.1 Market, 2017 - 2028 (USD Million)5.4 Tertiary Data Analysis5.4.1 Market, 2017 - 2028 (USD Million)5.4.2 Variant annotation5.4.2.1 Market, 2017 - 2028 (USD Million)5.4.3 Application-specific data analysis5.4.3.1 Market, 2017 - 2028 (USD Million)5.4.3.2 Targeted sequencing/gene panel5.4.3.2.1 Market, 2017 - 2028 (USD Million)5.4.3.3 Exome sequencing5.4.3.3.1 Market, 2017 - 2028 (USD Million)5.4.3.4 RNA sequencing5.4.3.4.1 Market, 2017 - 2028 (USD Million)5.4.3.5 Whole genome sequencing5.4.3.5.1 Market, 2017 - 2028 (USD Million)5.4.3.6 ChIP-sequencing5.4.3.6.1 Market, 2017 - 2028 (USD Million)5.4.3.7 Others5.4.3.7.1 Market, 2017 - 2028 (USD Million)Chapter 6 NGS Data Analysis Market: Mode Estimates and Trend Analysis6.1 NGS Data Analysis Market: Mode Movement Analysis6.2 In-house Data Analysis6.2.1 Market, 2017 - 2028 (USD Million)6.3 Outsourced Data Analysis6.3.1 Market, 2017 - 2028 (USD Million)Chapter 7 NGS Data Analysis Market: Read Length Estimates and Trend Analysis7.1 NGS Data Analysis Market: Read Length Movement Analysis7.2 Short Read Sequencing7.2.1 Market, 2017 - 2028 (USD Million)7.3 Long Read Sequencing7.3.1 Market, 2017 - 2028 (USD Million)7.4 Very Long Read Sequencing7.4.1 Market, 2017 - 2028 (USD Million)Chapter 8 NGS Data Analysis Market: End-use business analysis8.1 Market: End-use Movement Analysis8.2 Academic Research8.2.1 Market for academic research, 2017 - 2028 (USD Million)8.3 Clinical Research8.3.1 Market for clinical research, 2017 - 2028 (USD Million)8.4 Hospitals & Clinics8.4.1 Market for hospitals & clinics, 2017 - 2028 (USD Million)8.5 Pharmaceutical & Biotech Entities8.5.1 Market for pharmaceutical & biotech entities, 2017 - 2028 (USD Million)8.6 Other Users8.6.1 Market for other users, 2017 - 2028 (USD Million)Chapter 9 NGS Data Analysis Market: Region Business AnalysisChapter 10 NGS Data Analysis Market: Company Profile10.1 Strategy Framework10.2 Market Participation Categorization10.3 Company Profiles10.3.1 QIAGEN10.3.1.1 Company overview10.3.1.2 Financial Performance10.3.1.3 Product benchmarking10.3.1.4 Strategic initiatives10.3.2 Illumina, Inc.10.3.2.1 Company overview10.3.2.2 Edico Genome10.3.2.2.1Company overview10.3.2.3 Financial performance10.3.2.4 Product benchmarking10.3.2.5 Strategic initiatives10.3.3 F. Hoffmann-La Roche Ltd.10.3.3.1 Company overview10.3.3.2 Financial performance10.3.3.3 Product benchmarking10.3.3.4 Strategic initiatives10.3.4 Thermo Fisher Scientific, Inc.10.3.4.1 Company overview10.3.4.2 Life Technologies Corp.10.3.4.2.1Company overview10.3.4.3 Financial performance10.3.4.4 Product benchmarking10.3.4.5 Strategic initiatives10.3.5 Agilent Technologies, Inc.10.3.5.1 Company overview10.3.5.2 Financial performance10.3.5.3 Product benchmarking10.3.5.4 Strategic initiatives10.3.6 Bio-Rad Laboratories, Inc.10.3.6.1 Company overview10.3.6.2 GnuBio10.3.6.2.1Company overview10.3.6.3 Financial performance10.3.6.4 Product benchmarking10.3.6.5 Strategic initiatives10.3.7 PierianDX10.3.7.1 Company overview10.3.7.2 Tute Genomics10.3.7.2.1 Company overview10.3.7.2.2 Knome, Inc.10.3.7.2.2.1 Company overview10.3.7.3 Financial performance10.3.7.4 Product benchmarking10.3.7.5 Strategic initiatives10.3.8 Intrexon Bioinformatics Germany GmbH10.3.8.1 Company overview10.3.8.2 Financial performance10.3.8.3 Product benchmarking10.3.8.4 Strategic initiatives10.3.9 Partek Incorporated10.3.9.1 Company overview10.3.9.2 Financial performance10.3.9.3 Product benchmarking10.3.9.4 Strategic initiatives10.3.10 Eurofins Scientific10.3.10.1 Company overview10.3.10.2 GATC Biotech GmbH10.3.10.2.1 Company overview10.3.10.3 Financial performance10.3.10.4 Product benchmarking10.3.10.5 Strategic initiatives10.3.11 Pacific Biosciences Of California, Inc.10.3.11.1 Company overview10.3.11.2 Financial performance10.3.11.3 Product benchmarking10.3.11.4 Strategic initiatives10.3.12 DNASTAR, Inc.10.3.12.1 Company overview10.3.12.2 Financial performance10.3.12.3 Product benchmarking10.3.12.4 Strategic initiatives10.3.13 Congenica Ltd.10.3.13.1 Company overview10.3.13.2 Financial performance10.3.13.3 Product benchmarking10.3.13.4 Strategic initiatives10.3.14 Fabric Genomics, Inc.10.3.14.1 Company overview10.3.14.2 Financial performance10.3.14.3 Product benchmarking10.3.14.4 Strategic initiatives10.3.15 Genuity Science10.3.15.1 Company overview10.3.15.2 Product benchmarking10.3.15.3 Strategic initiatives10.3.16 DNANEXUS Inc.10.3.16.1 Company overview10.3.16.2 Financial performance10.3.16.3 Product benchmarking10.3.16.4 Strategic initiatives10.3.17 Scigenom Labs Pvt. Ltd.10.3.17.1 Company overview10.3.17.2 Product benchmarking10.3.17.3 Strategic initiatives10.3.18 Golden Helix, Inc.10.3.18.1 Company overview10.3.18.2 Financial performance10.3.18.3 Product benchmarking10.3.18.4 Strategic initiatives
For more information about this report visit